Join the PKD Foundation as it hosts its first-ever Externally Led Patient-Focused Drug Development (EL-PFDD) Meeting on autosomal recessive PKD (ARPKD) and congentital hepatic fibrosis (CHF) on August 29. This is a unique opportunity for patients of all ages, care-partners, families, and friends of those living with PKD to provide the U.S. Food and Drug Administration (FDA) with their valuable perspectives. Patient input helps the FDA make informed decisions on approvals of potential medicines for ARPKD and steers pharmaceutical companies to design therapies and clinical trials that are meaningful for patients. Learn more pkdcure.org/el-pfddhttp://www.pkdcure.org/el-pfdd